OncLive TV

Andrew Kuykendall, MD, discusses the importance of testing for mutations in KIT and other genes in patients with systemic mastocytosis.

Nirav N. Shah, MD, discusses the investigation of lentiviral bispecific CAR T cells targeting CD20 and CD19 B-cell antigens in patients with relapsed or refractory mantle cell lymphoma.

Laura Dawson, MD, FRCPC, discusses the investigation of palliative radiotherapy for patients with symptomatic hepatocellular carcinoma or liver metastases.

Laurence Albigès, MD, PhD, discusses on the safety and efficacy of cabozantinib in patients with unresectable, locally advanced or metastatic renal cell carcinoma with a clear cell component.

Janeesh Sekkath Veedu, MBBS, discusses the survival advantage conferred by surgical-based treatment compared with definitive chemoradiation in patients with stage IIIA non–small cell lung cancer.

Burak Zeybek, MD, discusses key results and clinical implications from the phase 1 NOW trial investigating neoadjuvant olaparib in patients with newly diagnosed, BRCA-mutant ovarian cancer.

John L. Hays, MD, PhD, discusses the evolution of treating patients with hepatocellular carcinoma.

Ryan Kahn, MD, MHS, discusses the investigation of Newcastle disease virus encoded with interleukin 12 in ovarian cancer.

Bertrand Tombal, MD, PhD, discusses the pharmacokinetics of darolutamide plus docetaxel in metastatic hormone-sensitive prostate cancer.

Emma L. Barber, MD, discusses how key data from the phase 3 KEYNOTE-775 study improved the identification of patient populations within endometrial cancer that benefit from second-line immunotherapy.

Mary Katherine Montes de Oca, MD, discusses the use of cryocompression to reduce chemotherapy-induced peripheral neuropathy in gynecologic cancers.

Nader Sanai, MD, discusses symptoms associated with high-grade meningiomas, a rare brain tumor.

Priscilla K. Brastianos, MD, reviews recent findings in high-grade meningiomas, including data generated in her laboratory.

Anna C. Pavlick, DO, discusses the mechanism of action of vusolimogene oderparepvec in patients with anti–PD-1–failed cutaneous melanoma.

Siamak Daneshmand, MD, discusses the rationale for investigating erdafitinib in patients with recurrent, intermediate-risk non–muscle invasive bladder cancer harboring FGFR3 or FGFR2 alterations.

Christopher W. Ryan, MD, discusses the implications of updated findings from the phase 3 JAVELIN Bladder 100 trial in patients with locally advanced or metastatic urothelial cancer.

Terence Friedlander, MD, discusses the significance of the FDA approval of frontline enfortumab vedotin combined with pembrolizumab in patients with urothelial carcinoma.

Heather Lynn McArthur, MD, MPH, discusses key factors considered in the optimal sequencing of first and second line treatment option in patients with advanced triple-negative breast cancer.

Khaled Hassan, MD, discusses key results from the phase 1 CHRYSALIS trial of the bispecific antibody amivantamab-vmjw in non–small cell lung cancer expressing EGFR exon 20 insertion mutations.

Liat Hogen, MD, FRCSC, discusses the survival outcomes achieved with interval cytoreductive surgery following neoadjuvant chemotherapy in a study of patients with initial unresectable stage IV ovarian cancer.

Sarah Ackroyd, MD, MPH, discusses the rationale and key results from a study of time-related treatment burden in patients receiving treatment for advanced, recurrent endometrial cancer.

Beryl Manning-Geist, MD, discusses findings from a study evaluating the effects of primary treatment modality on secondary cytoreduction outcomes in patients with high-grade ovarian cancer.

Jung-Yun Lee, MD, PhD, discusses primary efficacy and safety findings from the phase 2 KGOG3046/TRU-D trial in patients with newly diagnosed ovarian cancer.

Brian Mitzman, MD, FACS, FCCP, discusses the use of adjuvant atezolizumab following platinum-based chemotherapy in patients with resectable non–small cell lung cancer.

Andrew Kin, MD, discusses the limitations and unmet needs associated with the use of BCMA-targeted therapies in relapsed/refractory multiple myeloma.

Nathalie McDowell Johnson, MD, FACS, discusses the accuracy of genomic testing in Black women with estrogen receptor-positive breast cancer.

Meghan K. Berkenstock, MD, discusses common ocular toxicities associated with the use of novel antibody-drug conjugates, and the subsequent development of mitigation strategies for these treatment-related adverse effects in gynecologic cancers.

Ursula A. Matulonis, MD, discusses common toxicities associated with mirvetuximab soravtansine-gynx, and how to properly manage these treatment-related adverse effects for patients with folate receptor alpha-high ovarian cancer.

Cara A. Mathews, MD, discusses 7-year overall survival data from the phase 3 SOLO-1 trial in patients with ovarian cancer.